NCT06298916View on ClinicalTrials.gov

64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

August 31, 2025

Primary Completion Date

November 30, 2025

Study Completion Date

April 30, 2026

Conditions
Metastatic SarcomaEsophageal CancerGastric CancerPancreatic CancerColorectal CancerSarcoma
Interventions
COMBINATION_PRODUCT

64Cu-LNTH-1363S

64Cu-LNTH-1363S, is a highly selective, high affinity FAP inhibitor (FAPi) that is radiolabeled with Copper-64 (64Cu) for PET/CT Imaging,

Trial Locations (5)

49503

RECRUITING

BAMF Health, Inc., Grand Rapids

91010

RECRUITING

City of Hope, Duarte

92868

RECRUITING

UC Irvine Health - Chao Family Comprehensive Cancer Center, Orange

94305

RECRUITING

Stanford Hospital & Clinics, Stanford

45229-3039

RECRUITING

Cincinnati Children's Hospital Medical Center, Cincinnati

Sponsors
All Listed Sponsors
lead

Lantheus Medical Imaging

INDUSTRY

NCT06298916 - 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Biotech Hunter | Biotech Hunter